We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Eden Research Plc | LSE:EDEN | London | Ordinary Share | GB0001646941 | ORD 1P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 3.80 | 3.60 | 4.00 | 3.80 | 3.80 | 3.80 | 205,010 | 08:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Biological Pds,ex Diagnstics | 3.19M | -6.49M | -0.0122 | -3.11 | 20.27M |
Date | Subject | Author | Discuss |
---|---|---|---|
16/9/2024 07:20 | Timbo_Slice, you're no good even at lying. You avidly wait for my every post, and scan it eagerly, no frantically, to find what I know and have found out. Clear as crystal. Now eff orf! And continue to think Bonkers Subsonic is your friend. :D :D :D | neutralpov | |
15/9/2024 20:39 | Neuts, can you please inject some humour otherwise you are going back on filter | money never sleeps | |
15/9/2024 20:01 | But don't worry. SUPERSONICO thinks you're great, and unlike him, you can spell! (chortle) | neutralpov | |
15/9/2024 19:58 | Timbo-of-many-fraudu Timbo-of-many-fraudu What does being THIS stoooooooooooooooooo ROTFLMAO @ sucker P.S. Repeatedly logging out and re-logging in with your different aliases so as to uptick your own idiotic posts makes you a MEGA-LUZER. :D | neutralpov | |
14/9/2024 15:43 | You seem blissfully unaware of your own mental state NPOV, as you hold no shares yet post repeatedly on a company you say is destined for zero pence. Thousands of posts and probably hundreds of hours. What a waste of your time. Hah hah hah | kittybiscuits | |
14/9/2024 09:06 | I'll book you both in for a double appointment | money never sleeps | |
14/9/2024 08:58 | Oh, just shut up already. And this company you keep desperately ramping, you know the one whose own directors don't buy its shares so you evidently think you are in a better position than they are to assess its prospects, has NOTHING WHATSOEVER TO DO WITH THE PANDEMIC (which was genuine) or COVID (which was/is real) or VACCINES (which, by and large, work) - all contrary to your assertions and implications. Seek professional help (esp. mental health) somewhere else. It is not available here, loon. :-) Would I be correct in guessing being severely mentally-ill helps one be a LTH here? ;-) | neutralpov | |
14/9/2024 08:55 | Just imagine the press when Science mag tells it's readers that Eden tech enhances the delivery capacity and effectiveness of Greenlight tech. | supersonico | |
13/9/2024 15:08 | 3LOGY – La soluzione intelligente e a basso impatto per controllare botrite, oidio e sclerotinia ................... Humair Tariq Follow Eden Research plc’s bio-fungicide #Mevalone, based on #Sustaine™ technology and exempt from Maximum Residue Limits (#MRL), also marketed as #3LOGY in Italy by our partner Sipcam Italia. It is one of the leading products for controlling botrytis, downy mildew, and powdery mildew in grapes (wine and table varieties) and various horticultural crops grown in open fields and greenhouses. | supersonico | |
13/9/2024 12:23 | We’ll find out soon enough. Investing is right, increased regions and greater product application uses will flatten that seasonal influence on Eden that will be a good thing. H2 has always historically been the stronger half. | kittybiscuits | |
13/9/2024 12:20 | REITERATED RESTATED REAFFIRMED TARGET SHARE PRICE EDEN RESEARCH plc LSE:EDEN ZERO PENCE (0.0000000000p) | neutralpov | |
13/9/2024 12:17 | Alchemy 13 Sep '24 - 13:00 - 18502 "I lingered on slide 9 myself recently. I’m still hoping H1 H1 yoy looks good." That people this STOOOOOOOOOOOOOOOOOO lol | neutralpov | |
13/9/2024 12:00 | I lingered on slide 9 myself recently.I'm still hoping H1 H1 yoy looks good. | alchemy | |
13/9/2024 11:12 | TrickyWhen will you admit that you are a paid stooge of Eden.Your posts are wholly misleading as to Edens prospects.You have been pumping this share for years, yet the price keeps falling, alongside massive shareholder dilution. will you tell everyone that there is a hole in Edens bucket. | ravenna23 | |
13/9/2024 10:55 | I wouldn't rely on H1 this year too much. The Company has always said H2 is more significant. In my opinion, two things will change that moving forward. 1) Ever increasing regulatory approvals and label extensions to even out geographical climate/seasons and the variability that will bring 2) The introduction of, initially, Ecovelex, followed by the insecticide. Bigger sales and not weather dependent as with Mevalone for Botrytis What I will be interested in is, any current/forward commentary post the trading period to indicate where we are in regards to expected announcements in H2 as detailed on slide 9 of this years AGM presentation. Finally, in the InvestorMeetCompany filmed live communication earlier this year, management did say that in their opinion, the shares are worth north of the 20p price target that has been presented by Cavendish. That is a 500% rise on where we are today. That has obviously not been picked up in a significant way, so a film that explores where that value is and details it so investors understand it properly and then ensuring that communication hits enough people, would be a welcome development. | investingisatrickygame | |
13/9/2024 10:19 | Nothing has changed with Eden. It is a company solely run for the benefit of Directors, you have yourself stated that they cannot be fired, despite their appalling performance. The product is too expensive. There is no financial benefit to users unless they produce an incredibly premium product. Make a sale to Chateau D'yquem, then perhaps success. However Eden cannot sell product at all. I have said this multiple times but nobody listens. Distribution is tied up with Corteva. It is in their interest for Eden to fail, then they can pick up the IP for nothing.Dream on Tricky. | ravenna23 |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions